Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016

Description: Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016

Summary

‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
- The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Respiratory Syncytial Virus (RSV) Infections Overview
Therapeutics Development
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
Ablynx NV
ADMA Biologics, Inc.
Agilvax, Inc.
Aridis Pharmaceuticals LLC
Artificial Cell Technologies, Inc.
AstraZeneca Plc
Aviragen Therapeutics, Inc.
Bavarian Nordic A/S
Celltrion, Inc.
Codagenix, Inc.
CureVac GmbH
DBV Technologies S.A.
Emergent BioSolutions Inc.
Enanta Pharmaceuticals, Inc.
Evec, Inc.
F. Hoffmann-La Roche Ltd.
GenVec, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Globavir Biosciences, Inc.
Humabs BioMed SA
iBio, Inc.
ILiAD Biotechnologies, LLC
Ilyang Pharmaceutical Co., Ltd
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
mAbxience S.A.
MedImmune, LLC
Medivir AB
Merck & Co., Inc.
Mucosis B.V.
NanoBio Corporation
Navigen Pharmaceuticals, Inc.
Novavax, Inc.
Panacea Biotec Limited
Profectus BioSciences, Inc.
Pulmocide Ltd
Regeneron Pharmaceuticals, Inc.
Romark Laboratories, L.C.
Sirnaomics, Inc.
Spider Biotech
Spring Bank Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
The International Biotechnology Center (IBC) Generium
Trellis Bioscience, Inc.
Vault Pharma Inc.
Vaxart, Inc.
VaxInnate Corporation
VBI Vaccines Inc.
Virometix AG
Visterra, Inc.
VLP Biotech, Inc.
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile
(influenza [virus like particle] + respiratory syncytial virus) vaccine - Drug Profile
AK-0529 - Drug Profile
ALS-8112 - Drug Profile
ALS-8176 - Drug Profile
ALX-0171 - Drug Profile
Antisense RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections - Drug Profile
AR-201 - Drug Profile
AZ-27 - Drug Profile
BTAC-585 - Drug Profile
danirixin - Drug Profile
DPX-RSV - Drug Profile
EV-046120 - Drug Profile
EV-046135 - Drug Profile
GBV-006 - Drug Profile
GNR-007 - Drug Profile
GSK-3003891A - Drug Profile
GSK-3389245A - Drug Profile
GV-2311 - Drug Profile
GXV - Drug Profile
influenza + RSV vaccine - Drug Profile
JY5-53718678 - Drug Profile
JNJ-61187165AAA - Drug Profile
JNJ-61187191AAA - Drug Profile
KIN-1400 - Drug Profile
MEDI-7510 - Drug Profile
MEDI-8897 - Drug Profile
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile
MPE-8 - Drug Profile
MV-012968 - Drug Profile
MVA-RSV - Drug Profile
nitazoxanide CR - Drug Profile
Oligonucleotide for respiratory syncytial virus vaccine - Drug Profile
Oligonucleotide for Respiratory Syncytial Virus-1 Infection - Drug Profile
palivizumab biosimilar - Drug Profile
palivizumab biosimilar - Drug Profile
palivizumab biosimilar - Drug Profile
palivizumab biosimilar - Drug Profile
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2016

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H1 2016

Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H1 2016

Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H1 2016

Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H1 2016

Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2016

Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Trellis Bioscience, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VaxInnate Corporation, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra, Inc., H1 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H1 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H1 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..3), H1 2016
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2016
List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2016

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3753860/](http://www.researchandmarkets.com/reports/3753860/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3753860/
Office Code: SCBR2HIB

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>☐</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Site License:</td>
<td>☐</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>☐</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: 
Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐ Last Name: 

First Name: 

Email Address: *

Job Title: 

Organisation: 

Address: 

City: 

Postal / Zip Code: 

Country: 

Phone Number: 

Fax Number: 

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World